SAN FRANCISCO – December 1, 2016 – Genesys® (www.genesys.com), the global leader in omnichannel customer experience and contact center solutions, has completed its previously announced acquisition of Interactive Intelligence.
Genesys and Interactive Intelligence have developed best-in-class customer experience capabilities as recognized by all leading industry analysts, with highly complementary solution portfolios. Now combined, Genesys is able to support customers of any size in all industries everywhere in the world with the most complete portfolio available in the cloud and on-premise. Genesys now has over 10,000 customers in more than 100 countries supporting over 25 billion customer interactions per year.
“With this announcement, Genesys ushers in a new era in customer experience,” said Paul Segre, chief executive officer of Genesys. “The combination of Genesys and Interactive Intelligence creates the largest innovation leader purely focused on delivering exceptional customer experiences. We’re pleased to welcome the Interactive Intelligence team.”
Any pharmaceuticals, including therapies for HIV, diabetes, all types of hepatitis and cancer, cardiovascular, skin, inflammatory, allergic, urological, bacterial and viral diseases, leukopoiesis stimulants, homeopathic medicines, as well Can I Take Cialis Generic (Tadalafil) Daily? as antiparasitic medicines
Tom Eggemeier, president of Genesys, added, “We’re excited about accelerating our mission to be an iconic company for our employees and customers. This combination propels Genesys into the next era as a top-50 employer with an industry-leading net promoter score, which is a key measure of customer satisfaction. We’ll continue to offer, support and invest in best-in-class solutions, including PureCloud®, Communications as a Service℠ (CaaS) and Customer Interaction Center™ (CIC), in addition to our core Genesys products.”
With the completion of the transaction, Paul Segre will continue to serve as CEO, providing leadership that best supports the needs of customers, partners and employees. Genesys will maintain its headquarters in Daly City, as well as key offices in Indianapolis, Indiana and Durham, North Carolina.
In accordance with the terms of the acquisition, Interactive Intelligence shareholders received $60.50 per share in cash for each share of Interactive Intelligence common stock they held at closing, for a total transaction value of approximately $1.4 billion. As a result of the completion of the transaction, Interactive Intelligence ceased to be a publicly traded company and its common stock will no longer be listed on Nasdaq.
Apotekeres rolle med hensyn til at sikre ansvarlig hjælp websted antibiotikabehandling inden for de eksisterende retlige rammer drøftes i en fælles rapport fra WHO og PGEU (2015)*. Den undersøgelse, der blev foretaget til rapporten, viste, at i 43 % af de lande, der deltog i undersøgelsen (19 ud af 44)
For more information about the acquisition completion, visit www.genesys.com/interactiveintelligence.